Current questions of thyroid diseases in childhood

2011 ◽  
Vol 152 (16) ◽  
pp. 617-627
Author(s):  
István Ilyés

In recent years our knowledge on thyroid diseases in childhood has been increased. Several forms of congenital hypothyroidism (dysgenesis, dyshormongenesis, thyrotropin resistance and some central forms) are consequences of gene mutations. Maternal hypothyroxinemia due to severe iodine deficiency leads to early neurological damage and congenital hypothyroidism. Neonatal screening of congenital hypothyroidism and early treatment with l-thyroxin ensure good prognosis. Differential diagnosis of the various forms of congenital hypothyroidism in newborns is not an easy task. The need for treatment of transient hypothyroxinemia is still controversial. Diagnosis of juvenile lymphocytic thyroiditis can be ascertained by the clinical status, ultrasound examination, detection of anti-peroxydase antibodies, evaluation of thyroid function, and fine needle aspiration cytology. L-thyroxin therapy is recommended in cases of subclinical and manifest hypothyroidism. The transient form of the rare newborn hyperthyroidism is the consequence of maternal Graves-Basedow disease. It can be a sever condition and its permanent form is caused by TSH-receptor gene mutation. In the pathogenesis of autonomic thyroid adenoma mutations of the TSH-receptor and the alpha subunit of the stimulatory G-protein are involved. Treatment of Graves-Basedow disease in childhood is a debated question. The first choice is medical treatment with antithyroid and beta-blocking drugs. However, remission rate is low under this therapy, and the disease is characterised by frequent relapses. For this reason, the necessity of definitive therapy frequently arises. In Europe subtotal thyroidectomy is used as second choice of therapy, but clinical experience in the United States showed that radioiodine treatment is a safe and effective therapy for children and adolescents. Iodine deficient goitre in childhood is a form of iodine deficiency disorder. It is the consequence of adaptation to iodine deficiency. It can be treated by iodine or/and l-thyroxin, and its development can be prevented by iodinated salt. In childhood, thyroid nodule needs for a detailed investigation because of the possibility of thyroid cancer. Medullar thyroid carcinoma indicates genetic screening in the patients and their family, and the presence of disease-causing RET-proto-oncogene mutation confirms the need for total thyroidectomy already in childhood. Orv. Hetil., 2011, 152, 617–627.

2020 ◽  
Vol 150 (9) ◽  
pp. 2429-2434
Author(s):  
James L Mills ◽  
Elijah C Reische ◽  
Kurunthachalam Kannan ◽  
Chongjing Gao ◽  
Gary M Shaw ◽  
...  

ABSTRACT Background Severe iodine deficiency or excess during pregnancy can cause congenital hypothyroidism (CH). Iodine deficiency is common in pregnant women in the United States. Objectives We conducted a nested case–control study in a cohort of ∼2.5 million births in California to determine whether iodine status is related to CH in a US population. Methods Dried blood spots from 907 newborns with CH identified by newborn screening and 909 unaffected controls matched by month of birth were obtained from the California Newborn Screening Program to measure whole-blood iodine concentration. Iodine status was compared between cases and controls, and logistic regression was used to assess the association between CH status and blood iodine concentrations. Iodine status was also compared between cases and controls among infants treated in a neonatal intensive care unit (NICU) because CH has been reported in infants exposed to high levels of iodine in the NICU. Results Blood iodine concentrations did not differ significantly between cases (median: 20.0 ng/mL; IQR: 12.1–29.8 ng/mL) and controls (median: 20.3 ng/mL; IQR: 12.5–30.9 ng/mL; P = 0.59). Neither extremely high nor extremely low blood iodine concentrations (1st, 5th, 95th, and 99th percentiles of the distribution) were more common in cases. Among infants treated in NICUs, however, cases had significantly (P = 0.01) higher iodine (median: 22.7 ng/mL; IQR: 16.4–32.1 ng/mL) compared with controls (median: 17.3 ng/mL; IQR: 8.3–26.6 ng/mL). Conclusions CH cases did not have significantly higher or lower iodine in this population, which is reassuring given that maternal iodine deficiency is common in the United States. Among newborns in the NICU, CH cases had higher blood iodine concentrations compared with controls, suggesting that excess iodine exposure in the NICU could be causing CH. It may be beneficial to monitor iodine exposure from surgical procedures, imaging, and iodine-containing disinfectants and to consider non-iodine alternatives.


Author(s):  
Stéphanie Larrivée-Vanier ◽  
Fabien Magne ◽  
Elwaseila Hamdoun ◽  
Anna Petryk ◽  
Zoha Kibar ◽  
...  

Abstract In three Somalian siblings with severe nongoitrous congenital hypothyroidism, exome sequencing identified a variant in TSHR predicted to be benign in isoform 3 but leading to an intronic mutation in isoform 1 (NM_00369:c.692 + 130C>A), which is the isoform expressed in the thyroid. This mutation creates a pseudo-exon that results in a protein that, if transcribed, would lack the transmembrane domain, thereby hampering its expression at the cell surface. Our findings illustrate that the interpretation of exome analysis requires knowledge of the relevant isoform expression and of the biology of the disease. This is the first description of a deep intronic mutation creating a pseudo-exon and inactivating the TSH receptor.


1996 ◽  
Vol 42 (1) ◽  
pp. 30-33 ◽  
Author(s):  
G. A. Gerasimov

Thyroxine is one of the 13 most commonly prescribed drugs in the United States. Thyroxine is even more frequently prescribed to patients in several countries of Western Europe, where, due to iodine deficiency, there is a high prevalence of thyroid diseases. Indication for the use of thyroxine is either conventional replacement therapy in patients with hypothyroidism, or blocking the secretion of thyroid stimulating hormone (TSH) in patients with nodular goiter or after surgery for thyroid cancer. Hypothyroidism is a common disease: according to foreign authors, from 1.5 to 2% of women and about 0.2% of men suffer from it. Among people over 60, the prevalence of hypothyroidism is even higher: up to 6% of women and 2.5% of men have a TSH level that is 2 times higher than the upper limit of normal. According to foreign studies conducted in areas without iodine deficiency (UK), thyroid nodules are found in 0.8% of men and 5% of women, and the frequency of nodes increases after 45 years. In areas with iodine deficiency in the biosphere, which includes the vast majority of the territory of Russia, the frequency of nodular goiter in women of reproductive age reaches 10% or more. Thyroid cancer is the most common endocrine localization of malignant tumors. In 1984, 10,000 new cases of thyroid cancer were reported in the United States. For a long time, the selection of thyroxine doses for substitution and suppressive therapy was purely empirical and was based mainly on clinical signs: dynamics of mass, pulse, disappearance of myxedema, etc. At present, there are objective methods for controlling the thyroxine dose.


1997 ◽  
Vol 99 (2) ◽  
pp. 186-190 ◽  
Author(s):  
B. Edman Ahlbom ◽  
Muhammad Yaqoob ◽  
Agne Larsson ◽  
Adam Ilicki ◽  
Göran Annerén ◽  
...  

1995 ◽  
Vol 80 (9) ◽  
pp. 2577-2585 ◽  
Author(s):  
J Van Sande ◽  
J Parma ◽  
M Tonacchera ◽  
S Swillens ◽  
J Dumont ◽  
...  

2021 ◽  
Vol 8 (4) ◽  
Author(s):  
Niyati H Shah ◽  
Kathleen A Shutt ◽  
Yohei Doi

Abstract Background Ampicillin-ceftriaxone (AC) has emerged as an alternative antibiotic regimen for enterococcal infective endocarditis (EIE) with reduced toxicity compared with ampicillin-gentamicin (AG), but evidence regarding its success in reducing EIE-associated death in the United States is limited. Methods We conducted a retrospective, propensity score–matched cohort analysis of EIE patients treated with AC or AG between 2010 and 2017 at 3 hospitals in Pittsburgh, Pennsylvania. We assessed all-cause 90-day mortality as the primary outcome and in-hospital mortality, length of hospital stay, hospital readmissions, adverse events, and relapse of bacteremia as the secondary outcomes. Results A total of 190 patients with EIE (100 treated with AC and 90 with AG) were included. Ninety-day mortality was significantly higher with AC than AG (21% vs 8%; P = .02). After propensity score matching, 56 patients in each group remained for the outcomes analysis. Documented aminoglycoside resistance, presence of annular or aortic abscess, and complete pacemaker removal were the significantly different variables between the 2 matched cohorts. We observed no statistically significant difference in 90-day mortality between the 2 treatment groups (11% vs 7%; P = .55). Adverse events were more common in patients treated with AG (25 vs 39; P = .0091), and more patients in the propensity score–matched AG cohort switched antibiotic regimens than in the AC group (10% vs 49%; P < .0001). Conclusions Patients treated with AC demonstrate no significant differences in mortality, treatment failure, or bacteremia relapse compared with AG in a propensity score–matched EIE cohort.


Sign in / Sign up

Export Citation Format

Share Document